Pharma
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
AstraZeneca announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the g...
Arecor signs exclusive licensing agreement for ready-to-dilute formulation of speciality hospital product AT351
Cambridge, UK, 30 December 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce an exclusive licensing agreement for AT351, a ready-to-dilute (RTD) liquid drug product, with a wh...
Arecor enters collaboration with major global pharmaceutical partner
Cambridge: Arecor Therapeutics plc, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a formulation study agreement with a major global pharmaceutical partner. ...
AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing
AstraZeneca announces an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that will further advance life sciences in China. ...
Arecor establishes partnership with Skye Bioscience to develop enhanced formulation of obesity candidate Nimacimab
Arecor Therapeutics plc, the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces a formulation development collaboration with Skye Bioscience, a clinical-stage biotechnology company focused on obesity and other metabolic health disorders. ...
Chinese biopharma out-licensing: Ushering in a new era for UK-China collaboration in 2025
Disclaimer: This article is intended for industry professionals and provides general educational information only. It does not promote specific products or constitute medical advice.Introduction ...
Her Royal Highness The Princess Royal Officially Opens Insmed’s New Research and Development Facility in Cambridge, UK
LONDON, Friday 18 July 2025, Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today welcomes the opening of a new research and developm...
Revenue growth continues - H1 and Q2 2025 results
Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said:“Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key Phase III trial readout...
The invisible infrastructure of innovation: Why Data Governance is foundational to the future of healthcare
Co-authored by Sebastian Sbirna, Novo NordiskIn the race to transform healthcare, technology steals the spotlight, AI-driven diagnostics, personalised medicine, and digital therapeutics dominate headlines. But behind the scenes, there is a quieter, less glamorous foundation upon which a...
Transforming patient care and provider efficiency
Co-authored Cassie McGrath, Morning Brew